Knowles
KN
30.94
-2.37
-7.12%
Knowles
US · KN
#2417 by market cap
Listed 1970
30.94
-2.37
-7.12%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.96, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Precision Devices is the largest reported line at 63.59% of revenue, across 2 reported segments.
- MedTech & Specialty Audio follows at 36.41%, so the top line still matters most but isn’t the whole story.
Revenue annual, last 8 years
Latest year +7.17% YoY
Margins
- Gross margin
- 43.21%
- Operating margin
- 12.36%
- Net margin
- 7.45%
Key ratios & quality
- Enterprise valuei
- 2.69B
- Altman Z-Scorei
- 5.96
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 826.90M | 854.80M | 764.30M | 868.10M | 478.80M | 456.80M | 553.50M | 593.20M |
| Gross profit | 322.60M | 328.00M | 271.20M | 359.50M | 227.00M | 203.80M | 234.80M | 256.30M |
| Selling & admin expenses | 142.50M | 145.70M | 131.50M | 146.40M | 106.30M | 125.80M | 142.00M | 142.80M |
| Research & development | 100.60M | 96.80M | 92.90M | 92.80M | 29.30M | 32.40M | 39.50M | 40.20M |
| Operating profit | 79.50M | 85.50M | 46.80M | 120.30M | 91.40M | 45.60M | 53.30M | 73.30M |
| Pretax profit | 61.10M | 66.30M | 11.30M | 104.60M | 87.70M | 37.30M | 34.70M | 64.00M |
| Tax | -4.50M | 16.60M | 8.40M | -45.60M | 21.30M | -28.30M | 11.30M | 13.10M |
| Net profit | 67.70M | 49.10M | 6.60M | 150.40M | -430.10M | 72.40M | -237.80M | 44.20M |
| Basic EPS | 1 | 1 | 0 | 2 | -5 | 1 | -3 | 1 |
| Diluted EPS | 0.74 | 0.53 | 0.07 | 1.59 | -4.69 | 0.79 | -2.67 | 0.50 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 145.90M | 152.90M | 162.20M | 153.10M | 166.80M | 184.00M |
| Gross profit | 60.60M | 69.90M | 72.50M | 67.10M | 74.60M | 81.30M |
| Selling & admin expenses | 35.90M | 34.00M | 35.70M | 39.40M | 39.20M | 39.40M |
| Research & development | 10.00M | 10.00M | 10.50M | 11.70M | 10.60M | 11.10M |
| Operating profit | 14.70M | 25.90M | 26.30M | 16.00M | 24.80M | 30.80M |
| Pretax profit | 11.30M | 22.30M | 29.60M | 11.00M | 22.60M | 27.80M |
| Tax | 3.50M | 4.30M | 4.10M | -300.00K | 4.20M | 6.60M |
| Net profit | 7.80M | 17.40M | 21.00M | 9.70M | 19.40M | 21.60M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.09 | 0.20 | 0.25 | 0.11 | 0.22 | 0.25 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 365.00M | 388.40M | 419.60M | 380.30M | 362.40M | 428.80M | 361.40M | 291.40M |
| Cash & ST investments | 73.50M | 78.40M | 147.80M | 68.90M | 48.20M | 87.30M | 130.10M | 54.20M |
| Inventory | 140.10M | 141.80M | 130.10M | 153.10M | 169.50M | 127.00M | 118.00M | 124.60M |
| Total assets | 1.55B | 1.65B | 1.65B | 1.73B | 1.18B | 1.46B | 1.12B | 1.05B |
| Total current liabilities | 141.80M | 151.50M | 297.30M | 166.20M | 99.10M | 164.60M | 197.60M | 105.90M |
| Short-term debt | 2.40M | 11.70M | 177.90M | 14.10M | 10.90M | 53.80M | 72.80M | 5.40M |
| Long-term debt | 158.10M | 156.80M | -- | 70.00M | 45.00M | 224.10M | 134.00M | 114.00M |
| Total liabilities | 336,300,000.00 | 366,100,000.00 | 351,400,000.00 | 272,100,000.00 | 191,000,000.00 | 428,700,000.00 | 362,200,000.00 | 275,300,000.00 |
| Total equity | 1.21B | 1.29B | 1.30B | 1.46B | 992.90M | 1.03B | 756.00M | 775.80M |
| Retained earnings | -224.20M | -175.10M | -168.50M | -18.10M | -448.20M | -375.80M | -613.60M | -569.40M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 334.80M | 334.20M | 291.40M | 297.40M | 324.30M | 330.10M |
| Cash & ST investments | 103.20M | 92.50M | 54.20M | 41.00M | 49.60M | 46.60M |
| Inventory | 119.70M | 123.90M | 124.60M | 136.20M | 147.10M | 150.30M |
| Total assets | 1.09B | 1.09B | 1.05B | 1.05B | 1.08B | 1.08B |
| Total current liabilities | 167.20M | 176.00M | 105.90M | 90.90M | 101.30M | 112.40M |
| Short-term debt | 74.70M | 76.10M | 5.40M | 4.90M | 4.50M | 4.40M |
| Long-term debt | 119.00M | 104.00M | 114.00M | 131.00M | 131.00M | 116.00M |
| Total liabilities | 342,200,000.00 | 336,400,000.00 | 275,300,000.00 | 273,700,000.00 | 280,500,000.00 | 276,900,000.00 |
| Total equity | 746.10M | 751.80M | 775.80M | 780.20M | 795.50M | 798.30M |
| Retained earnings | -607.80M | -590.40M | -569.40M | -559.70M | -540.30M | -518.70M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 98.50M | 123.90M | 128.10M | 182.10M | 86.30M | 122.70M | 130.10M | 114.00M |
| Depreciation & amortization | 52.40M | 54.40M | 60.60M | 62.50M | 53.90M | 46.50M | 50.30M | 36.30M |
| Free cash flow | 18.40M | 82.70M | 96.20M | 133.50M | 54.20M | 105.80M | 116.50M | 81.90M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -16.20M | -44.50M | -44.00M | -47.50M | -53.70M | -65.00M |
| Ending cash balance | 73.50M | 78.40M | 147.80M | 68.90M | 48.20M | 87.30M | 130.10M | 54.20M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 36.40M | 29.10M | 47.20M | -700.00K | 28.20M | 44.60M |
| Depreciation & amortization | 9.10M | 9.00M | 9.20M | 9.20M | 9.70M | 9.90M |
| Free cash flow | 31.30M | 21.40M | 31.90M | -11.50M | 21.70M | 37.30M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -30.00M | -20.00M | -10.00M | -7.50M | -15.00M | -25.00M |
| Ending cash balance | 103.20M | 92.50M | 54.20M | 41.00M | 49.60M | 46.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 5.78 | 3.93 | 0.51 | 10.89 | -35.08 | 7.14 | -26.57 | 5.77 |
| ROA %i | 4.37 | 3.07 | 0.40 | 8.88 | -29.50 | 5.47 | -18.43 | 4.08 |
| ROIC %i | 5.83 | 4.18 | 1.24 | 10.48 | -32.62 | 6.43 | -19.81 | 5.49 |
| 5-year avg ROE %i | -3.69 | -1.79 | 2.48 | 5.50 | -2.80 | -2.52 | -8.62 | -7.57 |
| EBIT margin %i | 9.40 | 9.55 | 3.72 | 13.71 | -54.13 | 7.41 | 9.90 | 12.98 |
| FCF / sales %i | 2.23 | 9.67 | 12.59 | 15.38 | 7.09 | 14.95 | 21.05 | 13.81 |
| Current ratioi | 2.57 | 2.56 | 1.41 | 2.29 | 3.66 | 2.61 | 1.83 | 2.75 |
| Quick ratioi | 1.51 | 1.57 | 0.94 | 1.30 | 1.85 | 1.08 | 1.19 | 1.48 |
| Debt / assetsi | 11.02 | 12.12 | 12.21 | 5.91 | 5.45 | 19.60 | 19.05 | 12.92 |
| LT debt / equityi | 13.88 | 14.65 | 1.86 | 6.05 | 5.40 | 22.52 | 18.55 | 16.81 |
| Interest coveragei | 4.68 | 5.33 | 1.66 | 8.26 | -96.26 | 7.08 | 2.73 | 5.92 |
| Revenue CAGR (3Y) %i | 3.14 | 4.19 | 0.89 | 1.63 | -17.57 | -15.77 | -13.93 | 7.40 |
| Net income CAGR (3Y) %i | -- | -- | -54.11 | 30.48 | -- | 122.19 | -- | -- |
| FCF CAGR (3Y) %i | 10.06 | 6.33 | 32.56 | 93.59 | -13.14 | 3.22 | -4.44 | 14.75 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 3.31 | 5.45 | 5.77 | 7.28 | 8.76 | 9.25 |
| ROA %i | 2.19 | 3.69 | 4.08 | 5.20 | 6.24 | 6.63 |
| ROIC %i | 3.67 | 5.37 | 5.49 | 6.94 | 8.09 | 8.54 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 9.64 | 10.95 | 12.98 | 14.00 | 15.20 | 15.21 |
| FCF / sales %i | 19.45 | 14.26 | 13.81 | 11.90 | 10.00 | 11.92 |
| Current ratioi | 2.00 | 1.90 | 2.75 | 3.27 | 3.20 | 2.94 |
| Quick ratioi | 1.22 | 1.14 | 1.48 | 1.65 | 1.64 | 1.50 |
| Debt / assetsi | 19.38 | 18.14 | 12.92 | 14.38 | 13.96 | 12.49 |
| LT debt / equityi | 18.25 | 16.13 | 16.81 | 18.79 | 18.32 | 16.27 |
| Interest coveragei | 3.33 | 4.27 | 5.92 | 7.29 | 8.77 | 9.83 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Precision Devices63.59%
MedTech & Specialty Audio36.41%
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Knowles discussion 0 comments